Court overturns legal aid refusal in psilocybin post-trial case, allowing a patient to challenge denied access to continued treatment after a clinical study ended

Psilocybin access after a clinical trial became the focus of a legal ruling when a court overturned a refusal of legal aid for a patient seeking continued treatment. The case centers on whether someone who benefited during a regulated study can challenge being cut off once the trial ends. The dispute links clinical research with health policy, patient rights, and the limits of compassionate or continued access pathways. Legal aid matters because it determines whether patients can realistically contest decisions made by public bodies or healthcare systems when promising psychedelic therapies remain outside routine approval. The ruling does not resolve long term access itself, but it raises the pressure on institutions to justify how post-trial care is handled. Psilocybin treatment sits at the center of a broader transition from experimental medicine to possible mainstream therapeutic use.